Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology for Diamond-Blackfan Anemia

Fulcrum Therapeutics Secures Exclusive Global License Agreement in Rare Hematology &nbsp In a significant development, Fulcrum Therapeutics, Inc. has recently announced the signing of an exclusive worldwide license agreement with CAMP4 Therapeutics Corp. The objective of this partnership is to advance the discovery, development, and commercialization of innovative therapeutic solutions for Diamo..